Advancements in Imaging and Therapeutic Options for Dry Age-Related Macular Degeneration and Geographic Atrophy-Reference-Cited by-同舟云学术

Advancements in Imaging and Therapeutic Options for Dry Age-Related Macular Degeneration and Geographic Atrophy

Published:2024-06-04 Issue:8 Volume:13 Page:2067-2082
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Servillo Andrea,Sacconi Riccardo,Oldoni Gloria,Barlocci Eugenio,Tombolini Beatrice,Battista Marco,Fantaguzzi Federico,Rissotto Federico,Mularoni Cecilia,Parravano Mariacristina,Zucchiatti Ilaria,Querques Lea,Bandello Francesco,Querques Giuseppe^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40123-024-00970-7.pdf

Reference67 articles.

1. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014. https://doi.org/10.1016/S2214-109X(13)70145-1.

2. Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–51. https://doi.org/10.1016/J.OPHTHA.2012.10.036.

3. Sacconi R, Corbelli E, Querques L, Bandello F, Querques G. A review of current and future management of geographic atrophy. Ophthalmol Ther. 2017;6:69–77. https://doi.org/10.1007/S40123-017-0086-6.

4. Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434–48. https://doi.org/10.1016/S0140-6736(23)01520-9.

5. Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402:1449–58. https://doi.org/10.1016/S0140-6736(23)01583-0.